Global Strategic Fund Ii L.... Net Worth

The estimated Net Worth of Global Strategic Fund Ii L.... is at least $98.8 Million dollars as of 1 July 2020. Global L owns over 116,467 units of Akero Therapeutics Inc stock worth over $77,719,602 and over the last 5 years Global sold AKRO stock worth over $21,086,357.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Global L AKRO stock SEC Form 4 insiders trading

Global has made over 13 trades of the Akero Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Global sold 116,467 units of AKRO stock worth $4,006,465 on 1 July 2020.

The largest trade Global's ever made was selling 494,000 units of Akero Therapeutics Inc stock on 13 January 2020 worth over $9,993,620. On average, Global trades about 90,100 units every 29 days since 2019. As of 1 July 2020 Global still owns at least 3,033,552 units of Akero Therapeutics Inc stock.

You can see the complete history of Global L stock trades at the bottom of the page.

Insiders trading at Akero Therapeutics Inc

Over the last 5 years, insiders at Akero Therapeutics Inc have traded over $146,260,704 worth of Akero Therapeutics Inc stock and bought 4,870,000 units worth $104,250,550 . The most active insiders traders include Group, Llc Green Jeremy Red..., Trust Blue Horizon Enterpri... und G. Walmsley Graham. On average, Akero Therapeutics Inc executives and independent directors trade stock every 11 days with the average trade being worth of $1,642,344. The most recent stock trade was executed by Jonathan Young on 3 September 2024, trading 5,000 units of AKRO stock currently worth $133,600.

What does Akero Therapeutics Inc do?

akero therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (nash) and other serious metabolic diseases. akero's lead clinical program, akr-001, is a long-acting fc fusion modified fgf21 protein and potential best-in-class treatment for nash. akr-001 builds upon two decades of work on fgf21 biology. it is designed to affect both the liver and adipose tissue, reducing liver fat and suppressing inflammation and fibrosis.

Complete history of Global L stock trades at Akero Therapeutics Inc

Akero Therapeutics Inc executives and stock owners

Akero Therapeutics Inc executives and other stock owners filed with the SEC include:

• Andrew Cheng,
  President, Chief Executive Officer, Director
• William White,
  Chief Financial Officer, Executive Vice President and Head of Corporate Development
• Timothy Rolph,
  Co-Founder, Chief Scientific Officer
• Jonathan Young,
  Co-Founder, Chief Operating Officer, Executive Vice President
• Dr. Andrew Cheng,
  Pres, CEO & Director
• Dr. Timothy Rolph,
  Co-Founder & Chief Scientific Officer
• Dr. Jonathan M. Young,
  Co-Founder, Exec. VP, COO & Sec.
• William R. White J.D.,
  Exec. VP, CFO, Treasurer & Head of Corp. Devel.
• Mark Iwicki,
  Independent Non-Executive Chairman of the Board
• Kevin Bitterman,
  Non-Executive Independent Director
• Seth Harrison,
  Non-Executive Independent Director
• Graham Walmsley,
  Non-Executive Independent Director
• Kitty Yale,
  Chief Development Officer
• Jane Henderson,
  Non-Executive Independent Director
• Tomas Heyman,
  Independent Director
• Kitty Yale,
  Exec. VP & Chief Devel. Officer
• John J. Schembri,
  VP of Fin. & Controller
• Venture Fund Xi, L.P. Atlas,
  10% owner
• Trust Blue Horizon Enterpri...,
  
• Venture Capital Vi, L.P.Ver...,
  
• Group, Llc Green Jeremy Red...,
  
• Global Strategic Fund Ii L....,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Aaron Royston,
  Director
• Venture Capital Vi, L.P. Ve...,
  10% owner
• Life Science Ventures, L.P....,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Venture Opportunity Fund I,...,
  10% owner
• Chou Judy,
  
• Catriona Yale,
  Chief Development Officer
• Yuan Xu,
  
• Scott A. Gangloff,
  Chief Technology Officer
• Patrick Lamy,
  Senior VP, Commercial Strategy